-
公开(公告)号:EP3873897B1
公开(公告)日:2024-08-14
申请号:EP19805082.5
申请日:2019-10-29
IPC分类号: C07D405/04 , C07C233/87 , C07D215/12 , C07D215/227 , C07D265/36 , C07D307/87 , C07D311/04 , C07D311/58 , C07D311/94 , C07D319/18 , C07D321/10 , C07D401/04 , C07D401/12 , C07D405/12 , C07D413/12 , C07D413/14 , C07D471/04 , A61K31/4709 , A61P29/00
CPC分类号: C07D405/04 , C07D405/12 , C07D413/12 , C07D413/14 , C07D319/18 , C07D321/10 , C07D307/87 , C07D311/58 , C07D311/04 , C07D311/94 , C07D265/36 , C07D215/12 , C07D215/227 , C07D471/04 , C07D401/04 , C07D401/12 , C07C233/87 , A61P29/00 , C07C2602/0820170501
-
公开(公告)号:EP3405458A1
公开(公告)日:2018-11-28
申请号:EP17700184.9
申请日:2017-01-13
发明人: PAZENOK, Sergii , VORS, Jean-Pierre , LEROUX, Frédéric, R. , ARIBI, Fallia , SCHMITT, Etienne , PANOSSIAN, Armen
IPC分类号: C07D215/12 , C07D215/18 , C07D215/20 , C07D215/26 , C07D215/36 , C07D215/38 , C07D221/10
CPC分类号: C07D215/12 , C07D215/18 , C07D215/20 , C07D215/26 , C07D215/36 , C07D215/38 , C07D221/10
摘要: The invention relates to a novel process for preparing polyfluoroalkylated quinolines from ketimines in the presence of fluoroalkylamino reagents.
-
公开(公告)号:EP2976333B1
公开(公告)日:2018-08-08
申请号:EP14770929.9
申请日:2014-03-13
发明人: COURCAMBECK, Jerome , BASSISSI, Firas , BRUN, Sonia , NICOLAS, Gregory , BERET, Antoine , PETIT, Serge , CAMUS, Claire , NALLET, Jean Pierre , HALFON, Philippe
IPC分类号: C07D401/04 , C07D401/14 , C07D215/46 , C07D413/14 , A61K31/47 , A61K31/4709 , A61K31/5377 , A61P35/00
CPC分类号: C07D215/52 , A61K31/47 , A61K31/4706 , A61K31/4709 , A61K31/5377 , A61K45/06 , C07D211/58 , C07D211/74 , C07D215/12 , C07D215/18 , C07D215/233 , C07D215/42 , C07D401/04 , C07D401/06 , C07D401/12 , C07D491/113
摘要: The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and non-neoplastic diseases.
-
公开(公告)号:EP2758416B8
公开(公告)日:2018-08-01
申请号:EP12775358.0
申请日:2012-09-20
发明人: BRANDSTADT, Kurt , COOK, Simon , NGUYEN, Binh, Thanh , SURGENOR, Avril , TAYLOR, Richard , TZOU, Ming-Shin , DASH, Aswini , OLSEN, Matthew
IPC分类号: C07F15/04
CPC分类号: B01J31/2295 , B01J31/0272 , B01J31/22 , B01J31/24 , B01J31/2414 , B01J31/2433 , B01J37/00 , B01J2231/323 , B01J2531/16 , B01J2531/17 , B01J2531/46 , B01J2531/49 , B01J2531/56 , B01J2531/64 , B01J2531/74 , B01J2531/821 , B01J2531/827 , B01J2531/842 , B01J2531/845 , B01J2531/847 , C07C209/66 , C07C213/08 , C07C217/92 , C07D213/32 , C07D213/38 , C07D213/53 , C07D215/12 , C07D271/06 , C07D295/135 , C07D307/52 , C07D333/22 , C07D413/10 , C07D413/14 , C07F1/00 , C07F1/005 , C07F1/08 , C07F3/06 , C07F7/00 , C07F7/0805 , C07F7/0838 , C07F7/0872 , C07F7/0879 , C07F7/0889 , C07F7/0896 , C07F7/1804 , C07F7/1876 , C07F9/5045 , C07F9/60 , C07F11/005 , C07F13/00 , C07F13/005 , C07F15/0033 , C07F15/0046 , C07F15/02 , C07F15/065 , C08G77/08 , C09K3/00 , G07F13/00
摘要: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.
-
公开(公告)号:EP3151821A4
公开(公告)日:2017-12-13
申请号:EP15802977
申请日:2015-06-05
申请人: UNIV KANSAS
IPC分类号: A61K31/166 , A61K31/175 , A61K31/655
CPC分类号: C07C243/38 , A61K47/6951 , C07C49/245 , C07C243/18 , C07D209/18 , C07D213/81 , C07D213/82 , C07D215/12 , C07D307/68 , C07D311/06 , C07D311/12 , C07D311/22 , C07D311/42
摘要: A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colorectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds.
-
6.SPHINGOSINE-1-PHOSPATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS 审中-公开
标题翻译: SPHINGOSINE-1-PHOSPATE受体调节剂治疗心血管疾病公开(公告)号:EP3209732A1
公开(公告)日:2017-08-30
申请号:EP15846300.0
申请日:2015-09-28
IPC分类号: C09B11/00
CPC分类号: C07D471/04 , C07C255/63 , C07D211/16 , C07D213/38 , C07D213/40 , C07D213/55 , C07D213/61 , C07D213/75 , C07D213/78 , C07D213/80 , C07D215/12 , C07D217/18 , C07D235/14 , C07D237/08 , C07D239/26 , C07D239/30 , C07D241/16 , C07D241/42 , C07D249/08 , C07D263/32 , C07D263/58 , C07D271/06 , C07D271/10 , C07D285/12 , C07D309/06 , C07D309/14 , C07D333/20 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C09B55/002 , C09B55/005 , C09B55/007
摘要: The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.
摘要翻译: 本发明提供了作为鞘氨醇-1-磷酸受体调节剂有效治疗心肺疾病如高血压(包括恶性高血压),心绞痛,心肌梗塞,心律失常,充血性心力衰竭,冠心病,动脉粥样硬化,心绞痛,心律失常 ,心肌梗塞(包括肥厚型心肌炎),心力衰竭,心脏骤停,支气管炎,哮喘,慢性阻塞性肺病,囊性纤维化,哮吼,肺气肿,胸膜炎,肺纤维化,肺炎,肺栓塞,肺动脉高压,间皮瘤,心室传导异常, 心脏传导阻滞,成人呼吸窘迫综合征,脓毒症综合征,特发性肺纤维化,硬皮病,系统性硬化症,腹膜后纤维化,预防瘢痕瘤形成或肝硬化。
-
7.
公开(公告)号:EP2794009B1
公开(公告)日:2017-08-30
申请号:EP12806515.8
申请日:2012-12-21
申请人: Kancera AB
IPC分类号: A61P35/00 , A61P29/00 , A61K31/381 , A61K31/41 , A61K31/18 , A61K31/343 , A61K31/427 , A61K31/4436 , A61K31/506 , C07C311/13 , C07C311/21 , C07C311/27 , C07C311/29 , C07C311/39 , C07C311/46
CPC分类号: C07D409/14 , C07C311/21 , C07C2601/16 , C07D213/34 , C07D213/71 , C07D213/74 , C07D215/12 , C07D231/38 , C07D261/14 , C07D277/26 , C07D285/15 , C07D295/088 , C07D295/096 , C07D295/192 , C07D307/64 , C07D307/79 , C07D307/82 , C07D333/22 , C07D333/34 , C07D333/62 , C07D405/04 , C07D409/04 , C07D409/12
-
公开(公告)号:EP2288615B1
公开(公告)日:2017-06-21
申请号:EP09749369.6
申请日:2009-05-21
发明人: AHLFORS, Jan-Eric , MEKOUAR, Khalid
IPC分类号: C07K7/06 , A61K31/223 , A61K31/47 , A61K31/5375 , A61K31/662 , A61K38/00 , C07C237/12 , C07C237/20 , C07C317/48 , C07D215/14 , C07D295/26 , C07F9/40 , C07K5/08 , C07K5/10 , C07K14/81 , C12N9/64
CPC分类号: C07K5/0819 , A61K38/00 , A61K38/005 , C07C271/22 , C07C317/50 , C07C2602/08 , C07D209/16 , C07D213/81 , C07D215/12 , C07D295/26 , C07F9/4006 , C07F9/6533 , C07K5/0202 , C07K5/06034 , C07K5/06052 , C07K5/06078 , C07K5/06104 , C07K5/06139 , C07K5/081 , C07K5/0812 , C07K5/1013 , C07K14/8139
摘要: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
摘要翻译: 本发明涉及式I,IA,II,IIA,III或IIIA的化合物及其药物用途。 本发明的具体方面涉及这些化合物用于选择性抑制一种或多种半胱天冬酶的用途。 还描述了其中式I,IA,II,IIA,III或IIIA的化合物用于预防和/或治疗受试者中的各种疾病和病症的方法,所述疾病和病症包括半胱天冬酶介导的疾病例如败血症,心肌梗塞, 缺血性中风,脊髓损伤(SCI),创伤性脑损伤(TBI)和神经退行性疾病(例如多发性硬化症(MS)和阿尔茨海默病,帕金森病和亨廷顿病)。
-
公开(公告)号:EP1737811B1
公开(公告)日:2016-08-10
申请号:EP05736159.4
申请日:2005-04-08
发明人: ALI, Amjad , BOHN, Joann , DENG, Qiaolin , LU, Zhijian , SINCLAIR, Peter, J. , TAYLOR, Gayle, E. , THOMPSON, Christopher, F. , QURAISHI, Nazia
IPC分类号: C07C271/16 , C07C205/00 , C07C229/00 , C07D213/64 , A61P9/10 , A61K31/44
CPC分类号: C07C271/20 , C07C233/18 , C07C271/16 , C07C271/22 , C07C279/08 , C07C311/04 , C07C311/08 , C07C317/32 , C07D209/08 , C07D213/40 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/89 , C07D215/12 , C07D215/26 , C07D217/02 , C07D217/14 , C07D261/08 , C07D271/06 , C07D307/52 , C07D307/79 , C07D333/20 , C07D333/22 , C07D333/28
-
公开(公告)号:EP2634177B8
公开(公告)日:2016-06-22
申请号:EP11836445.4
申请日:2011-10-28
申请人: CLINO Ltd.
IPC分类号: C07D215/20 , A61K9/08 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/5383 , A61K47/10 , A61K47/14 , A61K47/34 , A61K51/00 , A61P25/28 , C07D215/26 , C07D215/38 , C07D215/40 , C07D401/04 , C07D405/12 , C07D498/04
CPC分类号: C07D215/12 , A61K9/0019 , A61K9/08 , A61K51/0455 , A61K51/0459 , A61K51/0463 , C07B59/002 , C07B2200/05 , C07D215/14 , C07D215/20 , C07D215/233 , C07D215/26 , C07D215/38 , C07D215/40 , C07D401/04 , C07D405/12 , C07D405/14 , C07D498/04 , G01N33/6893 , G01N2800/2821
-
-
-
-
-
-
-
-
-